23/02/2026
Last week, we shared a publication from Gustave Roussy on pharmaceutical 3D printing in hospital settings. Today, we’d like to go one step further and break down the regulatory and quality framework they recently published to aid implementation in more hospitals.
One of the most impactful concepts proposed by the authors is treating the printable ink as a pharmaceutical intermediate, creating a practical bridge between hospital compounding and GMP environments.
This risk-based approach enables the implementation of semi-solid extrusion (SSE) 3D printing in real clinical settings, offering a realistic pathway toward patient-specific medicines produced directly at the point of care.
🔗 Read the full paper: https://lnkd.in/eCAxNVJ6
❓ Is your hospital considering pharmaceutical 3D Printing for their compounding workflows?